Complement-targeted therapeutics
Daniel Ricklin, John D. Lambris · Nature Biotechnology · 2007
Cited by 481 works. doi:10.1038/nbt1342
Authors
References
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
- The druggable genome
- Anesthesiology
- Complement
- Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis
- Estimating The Cost Of New Drug Development: Is It Really $802 Million?
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
- Partial Purification of a Serum Inhibitor of C'1-Esterase
- Complement
- Hereditary angioedema with normal C1-inhibitor activity in women